Abstract: Provided are compositions and methods for treating prostate conditions. The methods involve administering to an individual in need thereof a composition that contains i) an inhibitor of methionine salvage pathway in prostate of the individual and ii) a polyamine analogue. The methods are for use in individuals who have been diagnosed with, or are suspected of having or at risk for developing androgen sensitive prostate cancer (AS-CaP), or Castration recurrent CaP (CR-CaP), or benign prostate hyperplasia (BPH). The disclosure includes use of inhibitors of methylthioadenosine phosphorylase (MTAP), and a polyamine analog that upregulates polyamine catabolism by increasing spermidine/spermine N1-acetyl transferase (SAT1) activity, such as methyl-thio-DADMe-Immucillin (MTDIA), and 1),N(11)-bisethylnorspermine (BENSpm), respectively. Pharmaceutical formulations that contain a combination of the inhibitor of the methionine salvage pathway and a polyamine analogue are included, as are kits that contain such agents.
Type:
Grant
Filed:
May 17, 2016
Date of Patent:
June 29, 2021
Assignees:
Health Research, Inc., The Johns Hopkins University
Inventors:
Dominic Smiraglia, Haley Affronti, Robert Casero
Abstract: Described herein are pharmaceutical compositions including a proton pump inhibitor and an antiparasitic drug. In some embodiments, the compositions can be formulated as a non-solid for oral administration. The compositions can be used to treat gastrointestinal conditions. Methods of treatment using the compositions are also described.
Type:
Grant
Filed:
September 4, 2019
Date of Patent:
June 29, 2021
Assignee:
Adamis Pharmaceuticals Corporation
Inventors:
David Clayton Sutherland, James Kyle Zorn, Dennis J. Carlo
Abstract: The present invention is related to a method for treating an ocular disease, particularly a diabetes related ocular disease, comprising administering to a subject in need thereof an effective amount of a group of compounds having a structure of Formula A1, wherein the ocular disease is selected from the group consisting of proliferative vitreoretinopathy (PVR), uveitis, glaucoma and age related macular degeneration (AMD), and the diabetes related ocular disease is selected from the group consisting of diabetic retinopathy (DR) and diabetic macular edema (DME).
Abstract: Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.
Type:
Grant
Filed:
November 6, 2018
Date of Patent:
June 1, 2021
Assignee:
Evoke Pharma, Inc.
Inventors:
Matthew J. D'Onofrio, David A. Gonyer, Shirish A. Shah, Stuart J. Madden
Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
Abstract: The present invention primarily relates to the use of Homoeriodictyol (HED) or a salt thereof or a mixture of HED and one or more salts thereof or a mixture of several salts thereof for reducing the gastric acid secretion-stimulating effect of N-Acetyl-4-aminophenol (Paracetamol).
Type:
Grant
Filed:
April 19, 2017
Date of Patent:
May 25, 2021
Assignee:
SYMRISE AG
Inventors:
Joachim Hans, Jakob Peter Ley, Susanne Paetz, Silke Middendorf, Kathrin Liszt, Veronika Somoza
Abstract: The invention relates to dipeptidyl peptidase-4 inhibitors, including saxagliptin and sitagliptin, for use in the topical eye treatment and/or prevention of retinal neurodegenerative diseases, in particular diabetic retinopathy and its associated microvascular impairment. The invention also encompasses pharmaceutical topical eye compositions for use in the topical treatment and/or prevention of these diseases.
Type:
Grant
Filed:
April 28, 2017
Date of Patent:
May 25, 2021
Assignee:
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON—INSTITUT DE RECERCA
Inventors:
Rafael Simó Canonge, Cristina Hernández Pascual
Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.
Type:
Grant
Filed:
March 13, 2017
Date of Patent:
May 25, 2021
Assignee:
Oryzon Genomics S.A.
Inventors:
Filippo Ciceri, Serena Lunardi, Tamara Maes, Cristina Mascaro Crusat, Inigo Tirapu Fernandez De La Cuesta
Abstract: Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same.
Abstract: In some embodiments, therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress arginine methyltransferase CARM1. In some embodiments, the therapeutic treatments disclosed include methods comprising the step of administering a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor to a subject, including a human subject, wherein the cancer cells of the subject overexpress arginine methyltransferase CARM1. In some embodiments, the EZH2 inhibitors are administered in conjunction with platinum-based antineoplastic drugs.
Type:
Grant
Filed:
April 24, 2017
Date of Patent:
April 27, 2021
Assignee:
The Wistar Institute of Anatomy and Biology
Abstract: The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
Type:
Grant
Filed:
February 3, 2017
Date of Patent:
April 6, 2021
Assignees:
BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE INC.
Inventors:
Timothy A. Lewis, Alex Burgin, Monica Schenone, Xiaoyun Wu, Heidi Greulich, Matthew Meyerson, Luc De Waal, Antje Margret Wengner, Knut Eis, Philip Lienau, Ulrike Sack, Martin Lange
Abstract: Certain embodiments are directed to photo-activated compounds for the manipulation of pH in a cell. In certain aspects the photo-activated compound is 2-nitrobenzaldehyde (NBA). Photo-activated compounds can be used as a targeted therapy for a variety of disease states and conditions, such as cancer.
Type:
Grant
Filed:
February 26, 2015
Date of Patent:
March 16, 2021
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Matthew Gdovin, Brian O'Grady, Elma Frias, Haley Hazlett
Abstract: Provided are methods for treating or preventing a fibrotic disease selected from systemic sclerosis, cystic fibrosis, non-alcoholic steatohepatitis, Peyronie's disease, or interstitial lung disease; the method comprising administering a therapeutically effective amount of a compound of Formula (I) (wherein R1, R2, R3, R4, and R5 are as herein described) or a pharmaceutically acceptable salt thereof, to a patient in need of such therapy.
Type:
Grant
Filed:
May 12, 2017
Date of Patent:
February 23, 2021
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Raphaelle Berger, Guizhen Dong, Subharekha Raghavan, Zhiqiang Yang
Abstract: The inventor has discovered that a particular dosage of Alpha Glycerylphosphoryl Choline administered to adult males results in a reduction of thyrotropin serum. Thytotropin levels are depressed with increased dopamine levels in the brain, and CDP-choline has been shown to increase dopamine and dopamine receptor density in the CNS. By suppressing the TSH levels in the brain to increase dopamine levels, this invention can assist in the treatment of depression, as well as symptoms of hyperthyroidism such as chills, depression, sluggishness, or feelings of weakness.
Abstract: The present disclosure relates to osteoinductive putties and other implantable compositions for repair of bone defects and other medical uses. Specifically, the technology pertains to carriers for use in implantable compositions, such as osteoinductive putties. The osteoinductive putties are made entirely from donor tissue such as demineralized bone matrix, and the putties have excellent physical properties. The present disclosure relates to osteoinductive putties, carriers, compositions, implants, kits, methods of making and methods of using any of the foregoing.
Abstract: The disclosure relates to the field of lymphedema therapy, more specifically, to a new pharmacological strategy to rescue the failed lymph pump system that can supplement, enhance or replace current therapies.
Type:
Grant
Filed:
October 20, 2015
Date of Patent:
February 16, 2021
Assignee:
The Curators of the University of Missouri
Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A(A2A) receptor antagonist or a combination of an adenosine-A2A(A2A) receptor antagonist and a programmed cell death protein 1(PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2A receptor antagonist, a PD-1 signaling pathway inhibitor and a pharmaceutically acceptable excipient. Further provided are methods of detecting cellular effects, for example expression of pCREB, before, after or during adenosine receptor antagonist treatment.
Type:
Grant
Filed:
December 22, 2016
Date of Patent:
February 9, 2021
Assignee:
CORVUS PHARMACEUTICALS, INC.
Inventors:
Stephen Willingham, Richard A. Miller, Po Y. Ho, Ian McCaffery, Andrew Hotson
Abstract: Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations.
Type:
Grant
Filed:
April 26, 2019
Date of Patent:
January 5, 2021
Assignee:
THE CHILDREN'S MEDICAL CENTER CORPORATION